Klassen Preston
President & Head of R & D at Regulus Therapeutics Inc.; President & CEO at Metacrine, Inc.; EVP and CMO at ARENA PHARMACEUTICALS INC, and 1 more
- Sold, on record
- $1.7M
- Dollars the filings state
- Form 4 sales
- 6
- Latest Jan 13, 2025
- Form 144 notices
- 0
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- Regulus Therapeutics Inc.President & Head of R & D
- Metacrine, Inc.President & CEO
- ARENA PHARMACEUTICALS INCEVP and CMO
- Orexigen Therapeutics, Inc.SVP, Head Global Development
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Metacrine, Inc.425,353 shares
- Orexigen Therapeutics, Inc.100,000 shares
- Regulus Therapeutics Inc.31,445 shares
- ARENA PHARMACEUTICALS INC19,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Orexigen Therapeutics, Inc.UnusualMay 28, 2013 2013
Sold 28,771 shares at $7.21 ($207k)
Klassen Preston, SVP, Head Global Development
Sold 100% of holdings ($207k position)0 shares leftFirst sale on recordFiling
- 2 Form 4 sale Orexigen Therapeutics, Inc.UnusualJul 25, 2013 +58 days
Sold 71,229 shares at $7.16 ($510k)
Klassen Preston, SVP, Head Global Development
Sold 100% of holdings ($510k position)0 shares leftFiling
- 3 Form 4 sale ARENA PHARMACEUTICALS INCUnusualJan 8, 2019 +1993 days
Sold 19,000 shares at $42.06 ($799k)
Klassen Preston, EVP and CMO
Sold 100% of holdings ($799k position)0 shares leftFirst sale on recordFiling
- 4 Form 4 sale Metacrine, Inc.Plan not statedApr 19, 2022 +1197 days
Sold 44,748 shares at $0.50 ($22k)
Klassen Preston, President & CEO
Sold 4.6% of holdings ($484k position)922,510 shares leftFirst sale on recordFiling
- 5 Form 4 sale Metacrine, Inc.UnusualJan 26, 2023 +282 days
Sold 380,605 shares at $0.41 ($156k)
Klassen Preston, President & CEO
Sold 41.3% of holdings ($378k position)541,905 shares leftFiling
- 6 Form 4 sale Regulus Therapeutics Inc.RoutineJan 13, 2025 +718 days
Sold 31,445 shares at $1.26 ($40k)
Klassen Preston, President & Head of R & D
10b5-1 planSold 46.6% of holdings ($85k position)36,055 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2025 | Jan 15, 2025 | Regulus Therapeutics Inc. | President & Head of R & D | Form 4 sale | 31,445 | $40k | 46.6% | Routine | SEC |
| Jan 26, 2023 | Jan 27, 2023 | Metacrine, Inc. | President & CEO | Form 4 sale | 380,605 | $156k | 41.3% | Unusual | SEC |
| Apr 19, 2022 | Apr 20, 2022 | Metacrine, Inc. | President & CEO | Form 4 sale | 44,748 | $22k | 4.6% | Plan not stated | SEC |
| Jan 8, 2019 | Jan 8, 2019 | ARENA PHARMACEUTICALS INC | EVP and CMO | Form 4 sale | 19,000 | $799k | 100.0% | Unusual | SEC |
| Jul 25, 2013 | Jul 29, 2013 | Orexigen Therapeutics, Inc. | SVP, Head Global Development | Form 4 sale | 71,229 | $510k | 100.0% | Unusual | SEC |
| May 28, 2013 | May 30, 2013 | Orexigen Therapeutics, Inc. | SVP, Head Global Development | Form 4 sale | 28,771 | $207k | 100.0% | Unusual | SEC |